The Future of Athlete Health Starts Here
Harnessing the Biology of Recovery.
Protecting Elite to Everyday Athletes’ Desire to Move.
The Injury Crisis No One Has Solved
A Multi-Billion-Dollar Market Hiding in Plain Sight
Every year, millions of athletes — from professionals to weekend warriors — lose time, careers, and opportunities to injuries. Recovery science is the next frontier in human performance.
Temple Orthobio is pioneering TX-33, a first-in-class clinically proven therapeutic designed to prevent scar tissue-driven injuries and accelerate recovery across elite sports, weekend warriors, orthopedics, and human performance.
“Scar tissue is one of the biggest problems in sports medicine. The scientific work completed to date in humans is encouraging and makes this applicable in almost any orthopedic surgery. I can see this being used in every procedure where scar tissue is a potential issue. It is a game-changer.”
--Riley J Williams III, MD., Chief of Sports Medicine at Hospital for Special Surgery, NYC, and team physician for USA Basketball, Brooklyn Nets, Red Bull FC and FIFA 2026Large Unmet Market Opportunity: Injury, Recovery, & Performance (2 min video)
Highlights
Closed Seed Round and Received Approval on R&D Subsidy (55%-70%)
Co-founder is Chief of Sports Medicine at Hospital for Special Surgery, NYC
Clinical Validation in humans was achieved in abdominal surgeries
New patent family expires 2044
Team encompasses surgeons, scientists, engineers, business, and sports
“In sports, injuries affect both physical performance and the confidence athletes need to compete. Scar‑tissue formation is a major factor slowing return‑to‑play. A therapy like TX‑33 that addresses fibrosis could help athletes recover more efficiently—an advantage that matters whether you’re competing for a podium or simply trying to get back on the field.”
--Neville Wright, 3X Olympian, Canadian National Soccer Team Performance Therapist